Advertisement

Topics

Lynne Cohen Consortium Project: Multi-Center Database/Registry

2014-08-27 03:26:49 | BioPortfolio

Summary

Goals of this registry:

1.1 To collect and store very limited demographic information (age, birthdate, race and ethnicity), limited cancer risk and breast and ovarian disease history, as well as limited family history of breast and ovarian cancer on patients who are at risk of breast or ovarian cancer or who have had a diagnosis of either cancer,

1.2 To make available summary information (in an anonymous form) regarding the subjects in this registry to Consortium members, and other investigators, who can use these data to plan research projects and evaluate the feasibility of such projects,

1.3 To make available summary information (number of new patients seen in the clinic, number of mutations, number of preventive surgeries, average age of patients seen) to the Lynne Cohen Foundation for Ovarian Cancer Research, in order to document the numbers of subjects who utilize their supported clinics.

Description

Information Collection for Entry into Multicenter Registry:

If you agree to take part in this study, a study staff member will collect the following information by asking you at a clinic visit and checking your medical records. The following information will be entered in the registry:

your demographic information (your sex, year of birth, and race/ethnicity) whether any member of your family has a history of ovarian and/or breast cancer whether any member of your family has any known genetic markers that may mean a higher risk of developing a cancer a brief summary of your history of breast and/or ovarian disease and whether you have any known genetic markers that may mean a higher risk of developing breast and/or ovarian cancer a brief summary of the results of the clinic visit on the day you agreed to take part in this study (Day 1)

Follow-Up Information Collection:

Each time you visit the M. D. Anderson high-risk clinic (either the high-risk breast cancer clinic or the high-risk ovarian cancer clinic), the study staff will check your medical records and enter in the registry any updates to your cancer risk information. You will also be asked if any family members have been diagnosed with ovarian and/or breast cancer, and this will be entered in the registry.

If you miss any of your planned clinic visits, the study staff may contact you by phone to collect this information, contact you by mail to send you a questionnaire with this information, and/or reschedule your appointment. If you receive a questionnaire by mail, you will fill it out and mail it back to the research staff in the stamped, self-addressed envelope that will be provided to you. It should take about 5-10 minutes to complete.

Study Data:

The study staff plans to keep all personal identifying information (such as your name) strictly confidential. Your data will be handwritten on paper forms that will be stored in a locked file cabinet. The study staff will enter your data into the multicenter database (registry) with your participant identification (ID) number but not your name or other identifying information. The registry is password-protected. Only designated members of the study staff will have access to the participant ID numbers and be able to link the data to you. This is to allow medical information related to your data to be updated as needed. The linking information will be saved securely (on a password-protected computer) in the research office.

The multicenter registry is called the Lynne Cohen registry. It is maintained at the University of Southern California Norris Comprehensive Cancer Center.

Use of Registry for Planning Future Research:

Lynne Cohen clinics make up the multicenter group of clinics that are involved in this study. If a researcher at any Lynne Cohen clinic is planning to perform a research study involving ovarian or breast cancer causes or prevention, he or she can contact the Lynne Cohen Foundation. A staff member at the Lynne Cohen Foundation will check to see how many patients are included in the registry. This will help the researcher find out how many people the researcher may be able to ask to join his or her study. That number of people will also help the researcher decide if the planned study is feasible. The number of patients in the registry is the only information that will be shared with these researchers.

Length of Study Participation:

Your participation in this study will last for as long as you agree to keep having this study information collected.

When your participation in this study ends, the M. D. Anderson study staff will delete or destroy any personal identifying information and contact information collected. The rest of the study data will continue being stored in the registry.

This is an investigational study.

Up to 1000 patients will be enrolled in this multicenter study. Up to 200 will be enrolled at M. D. Anderson.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Conditions

Ovarian Cancer

Intervention

Questionnaire

Location

University of Alabama, Birmingham/Department of OB/GYN
Birmingham
Alabama
United States
35233

Status

Recruiting

Source

M.D. Anderson Cancer Center

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:26:49-0400

Clinical Trials [1823 Associated Clinical Trials listed on BioPortfolio]

Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer

The purpose of this study is to find out if complementary and alternative medicines (CAM) should be included with traditional therapy for women with ovarian cancer. Some of the alternative...

Ovarian Cancer Patient Questionnaire on Genetic Testing

The objective of this study is to evaluate the willingness of patients with ovarian cancer to undergo genetic testing, given the cost, their understanding and acceptance of genetic testing...

Elizabeth Registry for Low Grade Ovarian Cancer

Long-Term Objectives: - To establish an ongoing national research registry of epidemiologic, clinical and pathologic data on low grade and low malignant potential (LMP) ovarian ca...

Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for ovarian cancer. PURPOSE: Screening trial to determine the significance of CA 12...

Exhaled Breath Biomarkers in Finding Ovarian Epithelial Cancer in Patients With Newly Diagnosed Ovarian Epithelial Cancer, Polycystic Ovarian Syndrome, or Endometriosis and in Healthy Participants

RATIONALE: Studying samples of exhaled breath from patients with ovarian epithelial cancer, polycystic ovarian syndrome, or endometriosis and from healthy participants in the laboratory ma...

PubMed Articles [15153 Associated PubMed Articles listed on BioPortfolio]

MiR-19a negatively regulated the expression of PTEN and promoted the growth of ovarian cancer cells.

Ovarian cancer is the most lethal malignancy of the women genital tract. Exploring novel factors involved in the development of ovarian cancer and characterizing the molecular mechanisms by which regu...

Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.

Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger f...

LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions.

Ovarian cancer is the most frequent cause of death resulting from malignant gynecological tumors. After surgical intervention, cisplatin (DDP) is a major chemotherapy drug for ovarian cancer, but the ...

Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer.

Ovarian cancer is usually treated with transurethral resection or systemic chemotherapy in clinic. However, the development of drug resistance in ovarian cancer is frequently observed in ovarian cance...

Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.

Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evalua...

Medical and Biotech [MESH] Definitions

Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.

Self report questionnaire which yields 16 scores on personality traits, such as reserved vs. outgoing, humble vs. assertive, etc.

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.

Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.

Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.

More From BioPortfolio on "Lynne Cohen Consortium Project: Multi-Center Database/Registry"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...


Searches Linking to this Trial